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Spectropathology for the next generation:
Quo vadis?
Hugh J. Byrne,*a Malgorzata Baranska,b Gerwin J. Puppels,c,d Nick Stone,e
Bayden Wood,f Kathleen M. Gough,g Peter Lasch,h Phil Heraud,i Josep Sulé-Susoj
and Ganesh D. Sockalingumk
Although the potential of vibrational spectroscopy for biomedical applications has been well demon-
strated, translation into clinical practice has been relatively slow. This Editorial assesses the challenges
facing the ﬁeld and the potential way forward. While many technological challenges have been addressed
to date, considerable eﬀort is still required to gain acceptance of the techniques among the medical
community, standardise protocols, extend to a clinically relevant scale, and ultimately assess the health
economics underlying clinical deployment. National and international research networks can contribute
much to technology development and standardisation. Ultimately, large-scale funding is required to
engage in clinical trials and instrument development.
Introduction
Disease diagnostics have long relied on
visual diﬀerences in tissue appearance,
aided in modern histopathology and
cytology by optical stains and micro-
scopic technologies. However, such
approaches are based on changes in
tissue and cell morphology, often appar-
ent only at the later stages of disease
development, rather than the underlying
biochemical changes associated with
disease onset or aetiology. Optical tech-
niques for routine screening are particu-
larly suitable for more accessible
anatomical sites such as mouth and
throat, skin and cervix, but although
optical techniques such as colposcopy
for cervical or conventional oral examin-
ation for oral cancer are routinely used,
they have low sensitivity and specificity.
They rely on the trained eye of a clinical
specialist, and consensus between such
specialists can be low, particularly in the
early stages of disease onset.1 Spectro-
scopic techniques are based on changes
in underlying biochemical structure
and therefore potentially oﬀer a more
objective analysis, which is therefore
automatable and adaptable to routine
screening. In this context, fluorescence
spectroscopic techniques have received
considerable attention, although, for a
label-free technology, analysis is based
only on endogenous fluorophores such
as collagen, elastin, keratin, riboflavin,
porphyrin and NADH. Emission bands
are broad and overlapping, reducing the
specificities of such techniques. The use
of UV excitation also limits the sampling
depth in tissue. As an alternative,
vibrational spectroscopy, both infrared
absorption and Raman scattering, oﬀers
many potential advantages as it provides
a spectroscopic signature of all mole-
cular constituents of the sample, and as
such a complex fingerprint which can be
used to uniquely identify a compound,
collection of compounds, or subtle
changes to it or them.
The potential of vibrational spec-
troscopy for biomedical applications has
been well established through many
proof-of-concept studies over the past
decades.2–5 Due to its unique finger-
printing capability, vibrational spec-
troscopy can play a significant role in
histopathology, cytology, biopsy target-
ing, surgical targets, treatment monitor-
ing and drug studies. Application
scenarios could include single-shot
measurement of targeted nuclei for cyto-
logical screening, or in the imaging and/
or mapping of larger areas for diagnos-
tics or high content analysis, in vivo,
ex vivo or in vitro. However, translation
into the clinical environment has been
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slow, and it is appropriate at this stage
to assess and evaluate questions such as:
(i) What are the most achievable, stra-
tegic target applications?; (ii) What are
the technical challenges, and how can
they be addressed?; and (iii) What are
the challenges to implementation (legis-
lative, clinical trials etc.), and how can
they be addressed? This Editorial con-
siders such questions under the sub-
headings of (i) Translational research
into in-vivo clinical applications, (ii) Ex-
vivo tissue biopsies, body fluids and
cytological samples for diagnostics and
disease studies, and (iii) In-vitro cell
culture and 3D models for research and
medical applications.
(i) Translational
research into in-vivo
clinical applications
As an optical-based technology,
vibrational spectroscopy is easily adapt-
able to in-vivo disease diagnostics and
monitoring applications, ranging from
intra-operative assessment of auxiliary
lymph nodes using Raman spec-
troscopy6 to IR photoacoustic dermal
screening.7 Significant development of
Raman fibre probes for in-vivo diagnos-
tics and intra-operative patient monitor-
ing has been achieved in recent years.8
In the latter context, identification of
tumour margins has been highlighted as
a potentially significant aid to surgeons.
This has been shown in various forms
using fibres or microscope-based
approaches.
FTIR probes for surface analysis and/
or evanescent wave analysis of fluids are
available,9 although these are clearly
limited if lesions of interest are to be
found more than a few microns below
the surface.
Skin is the most accessible organ and
therefore should be a strategic target. In
addition to diagnostic applications,10
spectroscopy could provide significant
guidance for monitoring and optimising
transdermal drug delivery,11 as well as
understanding dermal toxicity from
external agents such as nanoparticles,
chemicals and radiation.12
The question should therefore be
posed: in terms of in-vivo clinical appli-
cations, is the vision right? If the per-
formance of the technology is
optimised, and applications demon-
strated with appropriate large-scale
studies, will there be uptake in a clinical
environment? There is a need to balance
the drive for technology development
from the research community with the
needs of the clinical environment. Are
there technological solutions looking for
a problem or clinical problems looking
for a solution?
In this context, it is important to
engage with the medical community to
establish firstly the demand for the tech-
nological solutions, and secondly, what
is the Minimal Viable Solution?
Researchers strive for both fast acqui-
sition rates and high-quality spectral
data, but in a surgical environment time
is of the essence, and so a fast, simple
spectroscopic modality, which is cheaper
and more cost-eﬀective but has a lower
sensitivity and specificity may be a viable
solution. This poses the question as to
how much of a compromise can be
made in terms of performance. While
values approaching 100% have been
quoted for laboratory-based studies, is
80% sensitivity/specificity suﬃcient in a
clinical setting? The required perform-
ance levels will depend on the specific
application (tissue type, screening/
biopsy targeting/margin assessment),
and therefore it is diﬃcult to establish a
generic Minimal Viable Solution. It is,
however, crucial to establish what the
realistic and actual current gold-stan-
dard performance is for a number of
specific strategic applications such that
spectroscopic performance can be
directly compared and evaluated with
these reference diagnostic techniques.
Realistic evaluations and comparisons of
variability and costs are also imperative.
This is something that was demon-
strated by providing kappa statistics of
the performance of the technique versus
a panel of expert pathologists.1
Most research studies to date have
been conducted on general-purpose
research instruments and there is a need
to develop and optimise commercial pro-
ducts to be trialled and validated. In this
context, reproducibility of systems is a
vital technical challenge to be addressed,
as is transferability of datasets between
systems. There is currently a huge gap
between the research community and
commercial/industrial partners. Big
medical diagnostic companies need to
be on board and engaged in the drive
towards strategic and targeted techno-
logical development.
Critically, while the research environ-
ment has demands on demonstrating
the reproducibility of data, the demands
of clinical deployment are substantially
more rigorous. Studies must, therefore,
be extended to use of a clinically appro-
priate scale and statistical analysis to be
considered meaningful. The statistical
and ethical plan needs to be outlined for
each study, which should include signifi-
cant sample sizes (∼150 patients) and
blind datasets, while outcomes should
detail sensitivity, specificity, AUC etc.
To date, the proof-of-concept has
been adequately demonstrated, but there
is a need to develop large (randomised
controlled) clinical trials for the tech-
nology to be adopted by the clinical
community. However, such trials carry
considerable cost implications, taking
into account implementation costs and
the cost of developing further studies;
the cost of (randomised) clinical trials
and the cost of bringing something to
market.
The field of diagnostic applications of
spectroscopy could potentially learn
from the successes and failures of other
technologies in the clinical field, and
engaging with large transnational organi-
sations such as the European Clinical
Research Infrastructures Network
(ECRIN: http://www.ecrin.org/) may help
guide the strategic development.
Funding is limited to translate and
develop technologies across the so called
‘valley of death’ to full in-vivo clinical
studies and implementation. Financing
of development on such a scale would
require the support and commitment of
national and international funders, the
medical community, instrument manu-
facturers and private funders. In order to
justify substantial funding, health econ-
omics need to be more critically explored
and addressed, and realistic business
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plans composed. In this context, the
identification of strategic target appli-
cations may be crucial.
There is also a need to raise aware-
ness of optical diagnostics within, and
better engage, the medical community,
through conferences like SPEC. This
includes surgeons, oncologists, medical
physics, chief executives of hospitals for
local implementation, and national
boards, e.g. NICE (the National Institute
for Health and Care Excellence) in the
UK. This can be done through personal/
local contacts, but also through advertis-
ing in the relevant clinical publications.
There is a need to create curiosity and
demand among the clinical community,
but the talks at SPEC can be technically
detailed and inaccessible for clinicians.
It is important to adopt clinical
language: power analysis, sensitivity/
specificity, ROCs, patient benefit. Pres-
entations need to be applications
focused and clinical sessions should be
held at the weekend to facilitate attend-
ance by medical professionals. Open,
targeted discussions with clinicians are
essential such that practitioners from
various clinical backgrounds can present
their work, the current state of the art
and the challenges faced, and so that
researchers can propose what spec-
troscopy has to oﬀer in relation to their
clinical needs and how it relates to their
approaches. There is a need to educate
the community better in the techno-
logies of optical/spectroscopic diagnos-
tics and data analysis. This is a current
need, but successful translation of the
technologies will also create a need for
training at medical-school level. An
accessible handbook on optical diagnos-
tics for various clinical specialities could
be valuable as an introduction to the
field.
It is equally important to increasingly
publish clinically relevant spectroscopic
studies in clinical journals and to
promote the technologies at clinical con-
ferences and at large medical diagnos-
tics exhibitions. Early adopters from the
clinical community can help in this
context, and also in developing relation-
ships with key thought leaders in the
field to further promote adoption of the
technologies within their clinical com-
munities. Where clinical trials have been
carried out, patients are powerful advo-
cacy groups!
The research community should also
seek publicity for their results using
public and social media wherever/when-
ever possible.
(ii) Ex-vivo tissue
biopsies, body ﬂuids and
cytological samples for
diagnostics and disease
studies
For the purposes of this discussion, ex-
vivo applications of vibrational spec-
troscopy are interpreted to include ana-
lyses of samples taken directly from the
body for diagnostic purposes, namely
tissue biopsies, cytological samples and
body fluids.
From a surgical point of view, an
alternative to in-vivo spectroscopic moni-
toring would be ‘near-patient’ screening
of tissue biopsies taken intra-operatively
to guide the surgeon in identifying
tumour margins. Ideally, analysis should
be performed on fresh tissue, and the
screening time, including data proces-
sing, should be kept to a minimum. As
in the case of in-vivo measurement, time
is of the essence, and so a fast, simple
spectroscopic modality, which is cheaper
and more cost eﬀective but has lower
sensitivity and specificity may be a viable
solution.
However, there is a lack of concrete
understanding of issues such as: What is
the competition? How much better can
spectroscopy be? Within what reason-
able timeframe for measurement? The
measurements should take a matter of
minutes otherwise their clinical utility
will be questionable. Surgeons cannot
aﬀord to wait.
Such demands of the speed of acqui-
sition and data processing are consider-
ably eased in applications for histological
screening, although it is recognised that
current mapping/imaging times of large
areas of tissue followed by current pre-
and post-data processing protocols need
to be improved,13 and, although signifi-
cant progress has been made, there is
much to be done in terms of standardis-
ing procedures and protocols.
The demands on the ability to rapidly
scan large areas of tissue probably cur-
rently favour the use of FTIR rather than
Raman spectroscopy for such applications.
In terms of sample presentation,
fresh frozen sections are recommended
as the tissue architecture and biochemis-
try is kept largely intact and, notably, the
lipidic information can be accessed.14
Furthermore, they are more amenable to
combining immunohistochemistry, pro-
teomics, and biospectroscopy. However,
clinically, fresh tissue is normally only
used for intra-operative work and
stained, fixed sections are preferred for
histopathology.15 Therefore, standar-
dised protocols for spectroscopic analy-
sis of Formalin Fixed Paraﬃn Processed
(FFPP) tissue samples are of paramount
importance. Notably, analyses of archived
tissue libraries may add much to under-
standing disease progression and patient
prognosis.
It has been demonstrated that it is
not necessary to remove the paraﬃn
to obtain usable spectral information,
particularly in the case of FTIR spec-
troscopy.16 Standard tissue microarray
protocols involve paraﬃn-embedded
tissue. Leaving the paraﬃn in place
reduces scattering artefacts and the
eﬀects of further variable removal of aro-
matic solvent-soluble components.
However, it may be argued that greater
consistency of spectral information is
achieved when sections are deparaﬃ-
nised. Deparaﬃnising also allows post-
staining of the sections, although it has
been demonstrated that the eﬃciency of
the deparaﬃnisation process can
depend on the tissue pathology.17 Never-
theless, even for research purposes, pro-
tocols for such tissue processing should
be maintained as close as possible to
those currently employed in the clinical
environment.
In the case of FTIR-based spectro-
histopathology, there remains much
debate on the questions of measurement
geometry, and therefore the optimum
choice of substrates. In terms of cost,
low-E reflective slides appear most
attractive, implying the use of a trans-
flection measurement configuration.
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However, questions have been raised
concerning additional spectral artefacts
which can result from the so called ‘Elec-
tric Field Standing Wave’ (EFSW) eﬀect
in such measurements,18 although it has
been argued that the eﬀects are dimin-
ished by thickness inhomogeneities, the
range of sampling angles, and the
source incoherence.19 The alternative,
transmission, geometry requires (at least
partially) transparent substrates. It has
been demonstrated that even glass sub-
strates may provide transmission in a
suﬃciently broad (high-wavenumber)
region to provide diagnostic capabili-
ties.20 However, access to the broader
spectrum is only provided by more costly
polycrystalline substrates such as CaF2.
Choice of substrate may ultimately be
dictated by cost, and therefore by sample
throughput, and consequently by the
target application. A full-cost analysis is
required to assess the relative demand
and costs of applications for (i) near-
patient intra-operative diagnostics, (ii)
post-operative histological and (iii)
research purposes.
Cytological screening is commonly
employed as a routine preventative
measure or for early-stage disease detec-
tion, notably for cervical and oral
disease. In the case of cervical cytology,
screening programmes are well esta-
blished in the ‘third world’ and so sample
throughput is very high. This puts
increased demands on the cost eﬀective-
ness of alternatives to currently
employed clinical practice.
Cervical screening is traditionally per-
formed by the Pap smear methods, or
more recently by liquid-based methods
such as SurePath® or ThinPrep®. In all
cases, the samples are stained by a com-
bination of dyes. The Pap smear test is
reported to provide a sensitivity of ∼72%
and specificity of ∼94%.21 Studies of the
accuracy of liquid-based monolayer
cytology report a sensitivity of ∼63% and
a specificity ∼85%.21,22 The aetiology of
the disease in the case of cervical
cytology is predominantly linked with
HPV infection, and so screening for HPV
infection has become increasingly
popular, although, as it is more costly
the procedure is most often used as a
further screen of suspicious cytological
tests. Studies of the accuracy of HPV
testing report a sensitivity of ∼90% and
a specificity of ∼80%.22,23
The use of vibrational spectroscopy as
an adjunct or alternative to currently
employed cytological screening methods
may be a viable strategic target objective.
Sensitivities and specificities of >90% as
well as sensitivity to HPV infection have
been reported.24,25
The use of glass slides for high
throughput in all current clinical prac-
tices, as well as the smaller spot-size/
higher spatial resolution may favour the
use of Raman spectroscopy in this case.
Raman can potentially selectively target
either cell nuclear or cytoplasmic
regions, although the denser nuclear
region provides greater diagnostic poten-
tial. In the development of Raman proto-
cols, the choice of wavelength is
intimately linked with the choice of sub-
strate, and it has been demonstrated
that although conventional glass micro-
scope slides have a substantial back-
ground at 785 nm, this is greatly reduced
at 532 nm.26
In unstained cytological samples,
532 nm causes negligible observable
damage to the samples over the
measurement period. However, photo-
damage due to absorption and/or large
fluorescent backgrounds due to clinical
stains presents a significant problem for
the use of Raman spectroscopy as an
adjunct to cytological screening. Stained
samples cannot be simultaneously opti-
cally and spectroscopically screened,27
suggesting that a fully automated pro-
cedure for unstained cell recognition,
spectral analysis and assessment may be
required.
Screening of body fluids is a further
ex-vivo application which is currently
attracting increasing attention and may
represent a strategic, achievable target.28
Suspended or dissolved analytes are
present in rather low concentrations,
however, and many studies to date have
been performed on dried samples.29,30
The analysis of such samples can suﬀer
from problems associated with the
chemical and physical inhomogeneity of
the deposit, reducing both reproducibil-
ity and sensitivity. Bulk ATR FTIR
measurements have been shown to
reduce such eﬀects,31 however, and
multi-well ATR devices have been pro-
posed to potentially oﬀer high-through-
put screening.
Concentration of samples using cen-
trifugal filtration devices has been
shown to oﬀer an alternative which
allows measurement of the analytes in
the native aqueous environment.
Although Raman appears most promis-
ing in this context, due to the relatively
lower contribution of the water,
suﬃcient concentration of the sample
also allows analysis of the fingerprint
region by FTIR.32 Centrifugal filtration
also allows fractionation according to
molecular weight of the constituent ana-
lytes, potentially allowing the targeting
of molecular biomarkers of disease.33
As for the case of in-vivo applications,
translation of technologies to clinical
practise will be critically dependent on
large-scale studies with clinically rele-
vant statistics. Diagnostic applications
rely heavily on multivariate statistical
classification methodologies and each
analytical protocol must be ‘trained’. For
each potential application, the data
can be influenced by the instrument,
sample presentation and preparation,
the measurement protocol and data pro-
cessing. It is critical therefore that a con-
sensus be reached on Standard
Operating Procedures, to include all of
these variables. Inter-laboratory and
even inter-instrument consistency and
transferability needs to be established.
Only then can large databases be esta-
blished for both translational and
research purposes.
There is also a need for extensive vali-
dation and prospective testing of data
pre-processing protocols as well as
classification and regression models. In
this context, using patient data, it is
impossible to know what is the ‘correct’
result. Simulated datasets could play a
key role in validating data pre-processing
methodologies, ensuring that the spec-
tral integrity is preserved.34,35 However,
while they can play a similar role in vali-
dating classification algorithms, corre-
lation with disease pathology and
patient prognosis still relies upon con-
sensus clinical standards. The use of
archived tissue banks for retrospective
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studies may play a critical role in esta-
blishing such a clear correlation.
There is much scope for instrumental
development, in collaboration with the
instrument companies. Ideally, instru-
mentation should be optimised for the
specific purpose, ultimately of auto-
mated ex-vivo screening of histological,
cytological or biofluidic samples.
However, clinicians may be adverse to
automated decision systems, and that
they need to be the ultimate arbiters.
There may also be a disadvantage in
some biophotonic-based diagnostics as
they do not generate a consumable
market, and thus it may be more
diﬃcult to garner support from some
companies. Much progress has, however,
been made in the continued develop-
ment of portable devices, particularly in
the case of Raman spectroscopy. This
may generate specific applications, for
example, in contamination-restricted
environments, and particularly in field
clinics.
(iii) In-vitro cell culture
and 3D models for
research and medical
applications
The definition of ‘ex vivo’ to include
tissue biopsies, cytological samples and
biofluids directly from the patient for
diagnostic purposes restricts the discus-
sion of ‘in vitro’ to cell culture models
for both research and medical appli-
cations. As such, direct clinical trans-
lation is probably limited, but,
nevertheless, such models can prove
invaluable for the development and vali-
dation of new measurement techno-
logies, measurement and data
processing and analysis protocols, and
ultimately the exploration of the limits
of the techniques in identifying and
screening biomarkers associated with
biological function and dysfunction. The
techniques may also provide valuable
information on, for example, radiation
and chemotherapeutic resistance, and
present opportunities in their own right
for potential applications in screening
for drug delivery mechanisms and
eﬃcacy, radiation damage and
toxicology,36–38 given the drive for a
reduction in the use of animal models
for evaluating toxicity, due to regulatory
developments in both the EU and US
(EU Directive-2010/63/EU and US Public
Law 106–545, 2010, 106th Congress) that
are generally based on the principle of
the 3 Rs: to replace, reduce and refine
the use of animals used for scientific
purposes. Therefore, there is currently
much promotion of the development of
in-vitro models which can accurately
indicate in-vivo results.
In terms of basic research tools, the
imperative for standardisation of
measurement protocols is not as urgent.
Nevertheless, it is important that the
spectral data acquired is representative
of the biochemical profile of the sample
and is free of ‘spectral artefacts’ which
may arise from the measurement geome-
try, substrate, or sample. Much has been
achieved over the past decade to under-
stand such artefacts,39,40 but there
remain significant issues to be
addressed. Ultimately, for successful
application for in-vitro drug or toxicity
screening, standard operating pro-
cedures (SOPs) will be required.
In the case of infrared spectroscopy,
the debate over the choice of measure-
ment geometry and hence the choice of
substrate is (at least) as relevant for ana-
lysis in vitro as it is for diagnostics ex
vivo. The transflection geometry appears
to maximise both multiple beam inter-
ference (e.g. EFSW) and scattering
eﬀects,18,40 although neither are comple-
tely absent in the transmission geome-
try. The severity of both is dependent on
the homogeneity of the sample,
although algorithms for the removal of
resonance scattering/reflection are well
established.34 In the research environ-
ment, cost is less of a consideration than
that for high-throughput routine clinical
screening and so, where possible, the
use of the more expensive polycrystalline
substrates (e.g. CaF2) in the transmission
geometry are recommended. Notably,
UV-grade CaF2 is also an optimum sub-
strate for Raman measurement.26
Measurement using ATR minimises
(although does not completely eradicate)
scattering artefacts and has been
gaining increased popularity, although
the sampling depth is limited.
In the case of Raman spectroscopy,
most instrumentation operates in a
back-scattering (microscopic) geometry,
and consideration of the influence of the
substrate depends on the sample thick-
ness and focal depth of the objective
employed, and where the substrate con-
tributions are significant they depend on
the source wavelength. Glass substrates
have been shown to be acceptable at
visible wavelengths. Although they can
contribute in the case of thin samples
(e.g. cytoplasm) the contribution can be
removed by careful preprocessing. In the
near-infrared, common microscope
slides contribute a strong background
which can completely obscure the
sample response, and normally quartz
or, ideally, UV-grade CaF2 is preferable.
26
In terms of sample preparation/pres-
entation, it is well accepted that
measurement of live cells is most desir-
able. In the case of infrared spec-
troscopy, the strong absorption of the
water bands in the region of ∼1600 and
3300 cm−1 presents a problem, although
it should be stressed that this does
not prohibit measurement of live
cells (or other aqueous-based biological
samples).32,41 Specifically designed
sample compartments can minimise the
extracellular pathlength and the use of
ultrabright synchrotron sources signifi-
cantly can improve signal to noise.41 In
Raman spectroscopy, contributions from
water are less of a consideration and live-
cell imaging in a buﬀer of complete cell
culture medium has been demon-
strated.42 It is important to note that,
although the signal is small, water
does contribute to the underlying back-
ground and careful preprocessing of the
data is essential, remembering that
water is also a constituent intracellular
component.
In both cases, given current techno-
logies, particularly in the case of Raman,
whole-cell studies at high spatial resolu-
tion can be protracted and, to avoid bac-
terial contamination, cell movement in
the liquid environment, etc., it may be
more advantageous to fix the cells before
measurement. A number of studies have
demonstrated that formalin fixation best
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and preserves, although not completely,
the biochemical integrity of the cells.43
Commercial tissue models, notably
for skin, are available and can aid in
research purposes. These can be
measured ‘live’, or can be processed as
normal tissue. They reduce sample varia-
bility compared to human or animal
samples and can be employed to opti-
mise measurement protocols, although
it should be emphasised they are not
exact replicas. Notably, in the case of
skin models, the basal layer is lacking in
melanin, and also the lipidic architec-
ture of the stratum corneum does not
well reproduce the barrier function of
real skin, limiting the suitability for per-
fusion studies.44
Notably, it has been increasingly
argued that 2D cell cultures are a poor
representation of the cellular environ-
ment in vivo, and that true cell mor-
phology and cell behaviours, such as
drug uptake and response, would be
much more closely mimicked in 3D cell
matrices. The use of such constructs
may also help us to better understand
cell/microenvironment interactions, and
the analysis of single cells in such
environments seems to partly circum-
vent the scattering issues which contri-
bute to scattering backgrounds in both
FTIR and Raman since the cells are no
longer isolated.
Independent of use in spectroscopic
research, it is important to develop and
optimise these models. In doing so, it is
important to note that the diﬀusion and
bioavailability of both cytotoxicological
assays and test substances in 3D matrices
must be considered, and adaption of the
protocols is necessary for direct compari-
son with the traditional 2D models.45
Nevertheless, such models represent an
exciting new development for in-vitro
models which better mimic in-vivo con-
ditions, and the emergence of IR tomo-
graphic image reconstruction using
synchrotron sources to image these struc-
tures holds great promise.46 The useful-
ness of Raman microspectroscopy ‘optical
sectioning’ should also be emphasised.
Whereas diagnostic applications rely
largely on classification or regression
algorithms, in-vitro applications can
potentially exploit the full analytical
capabilities of biospectroscopy. In this
context, maintaining the integrity of the
spectral information during data proces-
sing is imperative. As in the case of ex-
vivo measurements, data preprocessing
methodologies can, and should, be vali-
dated using simulated datasets. Ideally,
such datasets should include spectral
variability due to all potentially con-
founding experimental factors since
limits of detection may ultimately be
determined by such factors.47
Post-processing and analysis proto-
cols can similarly be validated and opti-
mised to ensure that they produce the
correct result.33,35 Simulated datasets
can be employed to explore and develop
the limits of biospectroscopy as an
analytical technique, for example, to
minimise the limits of detection of and
to maximise the specificity of regression
algorithms and feature selection based
on spectral biomarkers.47 With properly
validated analytical techniques, biospec-
troscopy could aspire to the realisation
of its potential as a truly label-free, high-
content screening technique based on
the field of ‘spectral-ohmics’.
Achieving such goals, as well as those
of clinical translation, relies much on
continued instrumental development.
Increased signal throughput and novel
sampling techniques, such as those
aﬀorded by Quantum Cascade Lasers in
IR48–50 and Bragg filters in Raman,51
may significantly reduce sampling times
over large areas. Emerging technologies
such as Surface Enhanced Raman Spec-
troscopy (SERS), Stimulated Raman
Spectroscopy and Coherent Anti-Stokes
Raman Spectroscopy (CARS) may simi-
larly impact on the sensitivity of data col-
lection.52 Atomic Force Microscopy-IR
(AFMIR) and Tip Enhanced Raman Spec-
troscopy (TERS) open up the realm of
nanospectroscopy for both IR and
Raman spectroscopy. At present, at least,
these developments are very much in the
research domain, however, and are most
applicable to in-vitro studies.
Summary
There are clearly many challenges facing
the field of diagnostic applications of
vibrational spectroscopy. Many of these
require a more significant engagement
between the broad range of stake-
holders, from academic research scien-
tists to clinical practitioners, and
including medical and spectroscopic
instrument manufacturers.
Raising awareness of the field
amongst the medical community can be
achieved by academic researchers by tar-
geting medical journals and confer-
ences, and similarly targeted series of
conferences can play a pivotal role in
bringing the communities together.
In the move towards establishing and
promoting SOPs, for measurement and
data-handling protocols, national and
international research networks such as
the UK EPSRC Network CLIRSPEC
(http://www.clirspec.org) and the EU
COST Action Raman4Clinics (http://www.
cost.eu/domains_actions/bmbs/Actions/
BM1401) can potentially make signifi-
cant headway. Such networks can also
address the question of what constitutes
robust statistics, to take account of popu-
lation variance rather than simply tech-
nical variance, blinded trials etc., and
these should be expressed in terms of
clinical language to encourage clinical
acceptance.
Ultimately, however, more targeted
engagement with the medical commu-
nity must be undertaken to establish
strategic target applications and per-
formance levels for Minimal Viable
Solutions. Notably, substantial funding
will be required to conduct large-
scale, multi-lab and -instrument inter-
comparisons and ultimately clinical
trials.
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